Skip to main content

Advertisement

Figure 4 | EJNMMI Research

Figure 4

From: A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT

Figure 4

Coronal slice microSPECT/CT images. Images of athymic mice with s.c. human tumor xenografts (solid arrows) with increasing HER2 expression at 24 h p.i. of 70 MBq (10 μg) of 111In-DOTA-trastuzumab [panels (a), (b), (c)] or 111In-DOTA-rituximab Fab [panel (d)]. (a) Mouse with MDA-MB-231 (left panel) and BT-20 (right panel) xenografts with low HER2 density (5.4 × 104 and 1.6 × 105 receptors/cell, respectively). (b) Mouse with MDA-MB-361 xenograft with intermediate HER2 density (5.1 × 105 receptors/cell). (c) Mouse with 15 to 18 mm diameter (left flank) and 5 to 10 mm diameter (right flank) SK-OV-3 xenografts with high HER2 density (1.2 × 106 receptors/cell). (d) Mouse with MDA-MB-361 xenograft with intermediate HER2 density (5.1 × 105 receptors/cell). Bladder radioactivity in panel (c) is indicated by broken arrow. Image acquisition time was 85 to 120 min and anaesthesia was induced and maintained by inhalation of 2% isoflurane in oxygen. Images were adjusted to approximately equal intensity.

Back to article page